OSTEOPROTEGERIN LEVEL IN SAUDI OBESE WITH INSULIN RESISTANCE AND DIABETIC TYPE 2 PATIENTS

Abstract

Osteoprotegerin (OPG) is a newly identified inhibitor of bone resorption. Recent studies indicate that OPG also acts as an important regulatory molecule in the vasculature. Plasma levels of OPG seem to be elevated in subjects with diabetes as well as in non-diabetic subjects with cardiovascular disease.
In our study we investigate the relationship between serum OPG level in obese with insulin resistance and in type 2 diabetic patients with and without nephropathy.
Methods: Ninety Saudi subjects aged (30-50 years) were included in our study consisting of 15 normal lean, 35obese with insulin resistance and 40 type 2 diabetic patients. Diabetic type 2 patients were further divided to two subgroups according to the presence or absence of microalbuminuria. Blood glucose, serum OPG, urea and creatinine levels were measured for each subject. In addition the microalbuminuria in over-night urine sample was measured in type 2 diabetic patients and blood insulin level in obese subjects.
Results: Serum OPG level was significantly elevated in obese with insulin resistance patients compared to control subjects (P<0.05), also serum OPG level significantly elevated in type 2 diabetic patients compared to control and obese with insulin resistance (P<0.05). In type 2 diabetic patients the serum OPG level was significantly elevated in type 2 diabetic patient with microalbiminuria compared with type 2 diabetic patient without microalbuminuria (P<0.05). In obese with insulin resistance patients there was a positive correlation between blood glucose level and serum OPG level (r = 0.49).
In conclusion, our data showed that OPG serum levels increase in type 2 diabetic patients and high level of OPG appear in type 2 diabetic patients with microalbuminuria.
Key words: Osteoprotegerin, Diabetic type 2, Insulin resistace.